不同剂量普伐他汀对急性冠状动脉综合症血脂及vWF因子的影响  

Effects of different administration of Pravastatin on blood fat and vWF factor of patients with acute coronary syndromes

作　　者：蒋飞吉 唐建军[2] 邹小春[1] 

机构地区：[1]湖南省永州市人民医院,湖南永州425006 [2]中南大学湘雅二医院,湖南长沙410011

出　　处：《现代生物医学进展》2009年第20期3932-3934,3926,共4页Progress in Modern Biomedicine

摘　　要：目的:探讨不同剂量普伐他汀对早期急性冠状动脉综合症患者血脂及血浆vWF水平的影响。方法:将120例冠状动脉综合症患者随机分为:常规治疗组(30例)和普伐他汀治疗组(90例)。常规治疗组采用阿司匹林、硝酸酯类、血管紧张素转换酶抑制剂等,普伐他汀治疗组是在常规治疗基础上加用普伐他汀,按照普伐他汀的剂量又分为:10mg/d、20mg/d和40mg/d三组,持续用药4周。检测治疗前后患者的hs-CRP、HDL-C、LDL-C、TC、TG与vWF等因子水平的变化。选取30例健康人作为对照组。结果:与正常组或常规治疗组相比,急性冠状动脉综合症患者治疗4周后,普伐他汀组中患者的hs-CRP、LDL-C、HDL-C、TC、TG与vWF因子的水平变化的差异均有统计学意义(P<0.05)。在普伐他汀使用的三个剂量中,以20mg/d治疗组的治疗效果相对最好(P<0.05),副作用相对较小。结论:常规药物联合中等剂量的普伐他汀治疗早期急性冠状动脉综合症可获得良好的疗效,且安全性高,值得推广。Objective： To investigate the effect of different administration of Pravastatin on blood fat and vWF factor of patients with early acute coronary syndromes. Methods： One hundred and twenty acute coronary syndromes cases were divided into two groups by random method, 30 in conventional therapy group and 90 in Pravastatin group. The conventional therapy group was treated by cure medicine including Aspirin, nitrate, angiotensin converting enzyme inhibitor, and so on. The Pravastatin group, besides the conventional therapy, was treated with Pravastatin. The Pravastatin group was also subdivided into 3 groups with a different dosage of 10 rag/d, 20 mg/d and 40 mg/d respectively. After four weeks, pre/pro-therapy levers of hs-CRP, TC, TG, LDL-C, HDL-C and vWF of the cases were detected. Thirty healthy adults were treated as the control. Results： After four weeks of treatment, the levels of the hs-CRP, TC, TG, LDL-C, HDL-C and vWF in the Pravastatin group were different with statistical significance from that in conventional therapy group and control group （P〈0.05. Between the three subgroups of Pravastatin group, the subgroup treated with a dose of 20 mg/d achieved the best effect. Conclusion： Conventional medicine combined with a relatively low dose of Pravastatin had a good therapeutic efficacy on early acute coronary syndromes.

关 键 词：急性冠状动脉综合症 普伐他汀 LDL-C VWF因子 

分 类 号：R541[医药卫生—心血管疾病]